Compare UVE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | GERN |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 821.1M |
| IPO Year | 1996 | N/A |
| Metric | UVE | GERN |
|---|---|---|
| Price | $38.95 | $1.27 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $40.00 | $2.17 |
| AVG Volume (30 Days) | 201.2K | ★ 14.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $1,603,915,000.00 | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $2.88 | $43.75 |
| P/E Ratio | $21.09 | ★ N/A |
| Revenue Growth | ★ 5.48 | N/A |
| 52 Week Low | $21.96 | $1.04 |
| 52 Week High | $41.96 | $2.01 |
| Indicator | UVE | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 32.94 |
| Support Level | $38.29 | $1.24 |
| Resistance Level | $41.58 | $1.29 |
| Average True Range (ATR) | 1.18 | 0.09 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 27.15 | 10.42 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.